Fluorescence study continues in patients undergoing head and neck surgery

A leader in the field of nerve-targeted diagnostics and therapeutics has revealed it is progressing with a fluorescence study in patients receiving head and neck surgery.

Alume Biosciences, Inc., has revealed the first patient has been dosed a in Phase 3 Pivotal Study of ALM-488 (NCT05377554) in patients undergoing head and neck surgery.

ALM-488 is a peptide-dye conjugate designed to highlight nerves with fluorescence in real time during surgery.

Nullam et interdum sapien, eu facilisis erat. Etiam eget quam nisi. Integer imperdiet eros vel lorem pellentesque, non ornare libero aliquam. Phasellus nec urna molestie, pellentesque nisi at, volutpat odio. Mauris pulvinar efficitur neque at pretium. Nunc euismod turpis ante, et porttitor diam auctor sed. Ut erat metus, tincidunt a malesuada nec, blandit ut felis. Nullam pulvinar ac dolor at euismod. Curabitur scelerisque ac urna in cursus. Nulla nisi elit, consectetur a sem ac, laoreet condimentum massa
Register for free or to unlock this article
To gain full access to the only resource for industry news, simply register for free.
Already registered?
Connecting Surgeons.
Shaping the future.
connecting surgeons. shaping the future
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram